ClinicalTrials.gg
RecruitingNCT07945795Updated Nov 18, 2026

RDN for CKD and Uncontrolled Hypertension Trial

An interventional study of Radiofrequency Renal Denervation System and Parallel control in Hypertension and CKD - Chronic Kidney Disease, sponsored by Beijing Anzhen Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Beijing Anzhen Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Dec 2025, registered Oct 2026).
  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 410 studies in Hypertension with a site in China — 125 open to participants now, 148 under way, 12 of them phase 3. Hypertension · China.

Planned enrollment
156th of 308
248 · median 253
Started
2025
with 47 others
No phase
146 of 410
57 open now
Primary completion
2027-10
later than 106 of 147 live
Registered
408th of 410
by date
Lead sponsor
8 of 410
Beijing Anzhen Hospital

Among the 410 studies in Hypertension with a site in China, this one is the 156th largest by planned enrollment of the 308 interventional ones that give a count, is one of 48 that started in 2025, is one of 146 with no phase, reaches primary completion later than 106 of the 147 other live ones, and was the 408th registered.

Hypertension

6,125 studies on the registry are indexed under Hypertension; 910 are open to participants now.

Browse Hypertension studies →

Open to participants now

125 of the 410 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

119 more — sign in →

All 125 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 557 Hypertension studies recruiting now, 264 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 138 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 410 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

Prospective, Multi-Center, Randomized, Parallel-Controlled, Uptake clinical trial to evaluate the efficacy and safety of renal denervation in patients with uncontrolled hypertension and chronic kidney disease.

Read the detailed description

This Prospective, Multi-Center, Randomized, parallel-controlled uptake clinical trial aims to evaluate the efficacy and safety for renal denervation in patients with uncontrolled hypertension and chronic kidney disease, and to provide clinical evidence supporting the expansion of indications.

03

Conditions studied

  • Hypertension
  • CKD - Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged 18 to 65 years, inclusive, at the time of consent;
  2. Hypertensive subjects who have been taking 2 types of standardized antihypertensive drugs continuously and stably for at least 4 weeks, with office systolic blood pressure still ≥150 mmHg and \<180 mmHg, and 24-hour ambulatory mean systolic blood pressure (24h SBP) ≥135 mmHg and \<170 mmHg; or who have been taking ≥3 types of standardized antihypertensive drugs continuously and stably for at least 4 weeks, with office systolic blood pressure ≥140 mmHg and \<180 mmHg, and 24h SBP ≥130 mmHg and \<170 mmHg;
  3. Estimated (eGFR) ≥20 mL/min/1.73m² and \<60 mL/min/1.73m²;
  4. The presence or absence of accessory renal arteries is acceptable;
  5. The subject or his/her legal representative fully understands the content of the form for this trial and voluntarily signs the written informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding, or planning pregnancy during the study.
  2. Renal artery anatomy unsuitable for ablation (e.g., ≥50% stenosis, renal artery aneurysm, malformation, renal artery diameter \<3 mm, or treatable segment length \<20 mm).
  3. Subjects with a solitary kidney, prior renal transplantation, or requiring dialysis.
  4. Prior renal artery intervention or prior renal denervation.
  5. Other secondary hypertension not related to kidney disease (such as primary aldosteronism, pheochromocytoma/paraganglioma, Cushing's syndrome, thyroid disease, aortic coarctation, monogenic hypertension, renovascular hypertension, etc.).
  6. Allergic to contrast agents.
  7. Major surgery or trauma within 1 month before enrollment; acute coronary syndrome within 6 months; or planned surgery or cardiovascular interventional therapy within the next 6 months.
  8. Orthostatic hypotension.
  9. Type 1 diabetes mellitus.
  10. Primary pulmonary arterial hypertension.
  11. History of bleeding diathesis and haematological disorders or coagulopathy
  12. History of thromboembolic event within 6 months.
  13. History of stroke or (TIA) within 6 months.
  14. Severe peripheral arterial disease or unstable abdominal aortic aneurysm.
  15. Severe valvular heart disease or anticipated need for surgical valve replacement during the study period.
  16. Class III/IV heart failure at screening or hospitalization for exacerbation of chronic heart failure within the past six months.
  17. History of ventricular fibrillation, polymorphic ventricular tachycardia within six months, or prior implantation of an implantable cardioverter-defibrillator (ICD) or pacemaker.
  18. Acute kidney injury (AKI) within 4 weeks before enrollment or acute kidney disease ,AKI: ≥50% increase in serum creatinine within 7 days, or absolute increase ≥0.3 mg/dL (≥26.5 μmol/L) within 48 hours, or oliguria (\<0.5 mL·kg-¹·h-¹ for ≥6 hours).
  19. Severe hepatic dysfunction.
  20. Concomitant severe diseases that may interfere with study participation or affect survival, such as or AIDS.
  21. Known drug or alcohol dependence, difficulty understanding the study protocol, inability or unwillingness to comply with follow-up requirements.
  22. Current or planned participation in other clinical trials of drugs or medical devices (post-marketing registry studies permitted).
  23. Acute or severe systemic infection.
  24. Other conditions deemed unsuitable for participation by the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
248 participants (estimated)

Study arms

  • Experimental
    Renal Denervation (RDN)

    Participants receive percutaneous renal sympathetic denervation under digital subtraction angiography (DSA) guidance using a ultra-guiding radiofrequency denervation catheter. All participants receive a standardized antihypertensive regimen for ≥4 weeks before the procedure and thereafter per protocol. Follow-up visits occur at 7 days or before discharge, and at 1, 3, 6, 12 months.

    Device: Radiofrequency Renal Denervation System

  • Sham comparator
    Parallel control with sham operation

    Participants undergo a sham procedure: femoral artery puncture and selective renal angiography under DSA guidance are performed. The RF generator is connected to a dummy load, and activation sounds are emitted, but no energy is delivered. Participants remain on the procedure table for at least 35 minutes before sheath removal. Background standardized antihypertensive therapy is provided for ≥4 weeks pre-procedure and continued per protocol. Follow-up visits occur at 7 days or before discharge, and at 1, 3, 6, and 12 months.

    Procedure: Parallel control

Interventions

  • DeviceRadiofrequency Renal Denervation System

    DSA-guided percutaneous renal sympathetic denervation using a RF renal denervation system

    Also known as: Renal Denervation

  • ProcedureParallel control

    Sham procedure including femoral artery puncture and selective renal angiography; the radiofrequency generator is connected to a dummy load and produces activation sounds, but no energy is delivered. Minimum table time before sheath removal is 35 minutes.

    Also known as: Renal Angiography

06

What researchers measure

Primary outcomes

  1. Change from Baseline in 24-hour Ambulatory Systolic Blood Pressure at Month 6 (ABPM)

    24-hour mean systolic BP measured by validated ambulatory BP monitoring; change is Month 6 minus Baseline

    Time frame: Baseline to Month 6 post-procedure

Secondary outcomes

  1. Change from Baseline in 24-hour Ambulatory Diastolic Blood Pressure at Month 6 (ABPM)

    24-hour mean systolic BP measured by validated ambulatory BP monitoring

    Time frame: Baseline to Month 6 post-procedure

  2. Change from Baseline in Office Blood Pressure (including both systolic and diastolic BP)

    measured by validated office blood pressure monitoring

    Time frame: Baseline to Months 1, 3, 6 and 12 post-procedure

  3. Change from Baseline in 24-hour Ambulatory Systolic Blood Pressure (including both systolic and diastolic BP)

    24-hour mean systolic BP measured by validated ambulatory BP monitoring

    Time frame: Baseline to Months 1, 3, and 12 post-procedure

  4. Change from Baseline in Daytime and Nighttime Ambulatory Systolic Blood Pressure (ABPM)

    24-hour mean systolic BP measured in Daytime and Nighttime by validated ambulatory BP monitoring

    Time frame: Baseline to Months 1, 3, 6, and 12 post-procedure

  5. Percentage of Participants with 24-hour Ambulatory Systolic BP <130 mmHg

    24-hour mean systolic BP measured by validated ambulatory BP monitoring

    Time frame: Months 1, 3, 6, and 12 post-procedure

  6. Percentage of subjects with office systolic BP within the target ranges (<140 mmHg and <130 mmHg)

    measured by validated office blood pressure monitoring

    Time frame: Months 6 and 12 post-procedure

  7. Responder Rate: ≥5 mmHg Reduction in office Systolic BP

    Proportion of participants with a reduction ≥5 mmHg from baseline in office BP

    Time frame: Months 6 and 12 post-procedure

  8. Change from Baseline in Antihypertensive Medication Use

    Change in the number of concurrently prescribed antihypertensive agents

    Time frame: Months 1, 3, 6 and 12 post-procedure

  9. Change from Baseline in serum creatinine levels

    Change in postoperative serum creatinine levels relative to baseline

    Time frame: Months 1, 3, 6 and 12 post-procedure

  10. Changes from Baseline in glomerular filtration rate

    Changes in glomerular filtration rate relative to baseline

    Time frame: Months 1, 3, 6 and 12 post-procedure

  11. Changes from Baseline in the urine microalbumin-to-creatinine ratio

    Changes in the urine microalbumin-to-creatinine ratio relative to baseline

    Time frame: Months 1, 3, 6 and 12 post-procedure

  12. Change from Baseline in Heart Rate (by ECG)

    Resting heart rate measured by standard 12-lead ECG; change is Follow-up minus Baseline

    Time frame: Months 1, 3, 6 and 12 post-procedure

  13. Change from Baseline in left ventricular ejection fraction (LVEF) (by Echocardiography)

    by Echocardiography

    Time frame: Months 12 post-procedure

  14. Change from Baseline in left ventricular mass index

    by Echocardiography

    Time frame: Months 12 post-procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Oct 2027, 22 months after the start.

Of 1,406 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 22 months is close to that.

Counting every sponsor, half of 1,501 studies reached it within 23 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2026
First posted
Nov 18, 2026
StartActual
Dec 8, 2025
Primary completionEst.
Oct 31, 2027
CompletionEst.
Apr 30, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945795
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Dec 8, 2025
Primary completion
Oct 31, 2027 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Luyun Fan
Contact
katevan@163.com
+86-13522601484
Jingjing Zhou
Contact
zhoujjrf0901@163.com
+86-18742568090

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion